The newer generation of glucose-lowering agents, such as GLP-1 receptor agonists, enable many patients to reach glycaemic treatment goals, with cardiovascular risk reduction, and the additional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback